Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

BioDelivery Sciences International Inc. (BDSI - Snapshot Report) recently announced that it has finished enrolling patients in a pivotal pharmacokinetic study (BNX 103) being conducted with BEMA  buprenorphine/naloxone (BNX). The company also announced the completion of the clinical portion of the study. BNX is being evaluated for the treatment of opioid dependence.

Study participants have already been dosed and a plasma sample analysis is being conducted. BioDelivery intends to present results from the study before the end of September 2012.

According to an agreement with the US Food and Drug Administration (FDA), in February 2012, BNX-103 was designed to compare the relative bioavailability of buprenorphine and naloxone with the reference drug of Reckitt Benckiser Pharmaceuticals Inc.’s Suboxone.

BioDelivery expects the open-label safety study for the program BNX-103, to be completed by the end of 2012. Necessary product stability data from the study are expected to be available by the first quarter of 2013. The company is also planning for submission of the New Drug Application (NDA) in the second quarter of 2013.

We note that in January 2012, Endo Pharmaceuticals (ENDP - Analyst Report) inked a global license and development agreement with BioDelivery Sciences regarding the latter’s pain candidate BEMA buprenorphine. As per the terms of the deal, Endo Pharma is responsible for the manufacturing, distribution and commercialization of the candidate on a worldwide basis.

Following the deal, BioDelivery Sciences has received $30 million as an upfront payment. The $15 million payable by Endo Pharma, on the extension of BEMA buprenorphine’s patent protection period will result in Endo Pharma making payments worth $45 million under the deal. BioDelivery Sciences is eligible to receive a further $135 million in milestone payments in addition to royalties from Endo Pharma.

Our Recommendation

Currently, we have a Neutral recommendation on BioDelivery Sciences, which carries a Zacks #3 Rank (short-term ‘Hold’ rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%